BioArctic Ownership

BIOA-B Stock  SEK 210.60  2.60  1.25%   
BioArctic holds a total of 73.73 Million outstanding shares. BioArctic AB retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as BioArctic in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of BioArctic, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioArctic AB. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

BioArctic Stock Ownership Analysis

About 48.0% of the company shares are held by company insiders. The company last dividend was issued on the 10th of May 2019. BioArctic AB , a research intensive biopharmaceutical company, develops disease modifying treatments and diagnostics for neurodegenerative diseases in Sweden. BioArctic AB was founded in 1992 and is headquartered in Stockholm, Sweden. BioArctic is traded on Stockholm Stock Exchange in Sweden. For more info on BioArctic AB please contact the company at 46 86 95 69 30 or go to https://www.bioarctic.se.

BioArctic Outstanding Bonds

BioArctic issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioArctic AB uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioArctic bonds can be classified according to their maturity, which is the date when BioArctic AB has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Other Information on Investing in BioArctic Stock

BioArctic financial ratios help investors to determine whether BioArctic Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioArctic with respect to the benefits of owning BioArctic security.